The DOI matches its Crossref record; 107 of the 109 references it cites were found in a registry or an index.
FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0
Open accessAbstract
The purpose of these guidelines is to assist physicians in recommending, performing, interpreting and reporting the results of FDG PET/CT for oncological imaging of adult patients. PET is a quantitative imaging technique and therefore requires a common quality control (QC)/quality assurance (QA) procedure to maintain the accuracy and precision of quantitation. Repeatability and reproducibility are two essential requirements for any quantitative measurement and/or imaging biomarker. Repeatability relates to the uncertainty in obtaining the same result in the same patient when he or she is examined more than once on the same system. However, imaging biomarkers should also have adequate reproducibility, i.e. the ability to yield the same result in the same patient when that patient is examined on different systems and at different imaging sites. Adequate repeatability and reproducibility are essential for the clinical management of patients and the use of FDG PET/CT within multicentre trials. A common standardised imaging procedure will help promote the appropriate use of FDG PET/CT imaging and increase the value of publications and, therefore, their contribution to evidence-based medicine. Moreover, consistency in numerical values between platforms and institutes that acquire the data will potentially enhance the role of semiquantitative and quantitative image interpretation. Precision and accuracy are additionally important as FDG PET/CT is used to evaluate tumour response as well as for diagnosis, prognosis and staging. Therefore both the previous and these new guidelines specifically aim to achieve standardised uptake value harmonisation in multicentre settings.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The European and American guidelines for PET/CT imaging recommended the measurement of blood glucose level prior to scanning and rescheduling the examination whenever the level exceeds 200 mg/dL.[5,6]”
From Intrapatient variability of 18F-FDG uptake in normal tissues (2022) · cites this paper as [6]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Although all these errors are potentially severe, it should be noted that they can easily be avoided by following existing guidelines published by the EANM [24] or the EANM Research Ltd. (EARL) initiative [67].”
From Influences on PET Quantification and Interpretation (2022) · cites this paper as [24]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Interpretation of PET images in routine clinical practice primarily follows visual criteria, i.e., the assessment of generalized or focal pathologies in tracer accumulation, while quantitative parameters, including SUV, provide orientation or additional information at most [24].”
From Influences on PET Quantification and Interpretation (2022) · cites this paper as [24]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“European Association of Nuclear Medicine (EANM) [40] guidelines suggest if the plasma glucose level is higher than or equal to 200 mg/dl, the FDG PET/CT study should be rescheduled.”
From Effect of blood glucose level on standardized uptake value (SUV) in 18F-FDG PET-scan: a systematic review and meta-analysis of 20,807 individual SUV measurements (2019) · cites this paper as [40]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Current available PET-scan preparation protocols suggest rescheduling the scan or consideration of rapid-acting insulin injection prior to PET scan or scan rescheduling in patients with hyperglycemia ranging from 120 mg/dl to 200 mg/dl, and recommend inconsistent and diverse cut-offs for insulin injection or scan rescheduling [39,40].”
From Effect of blood glucose level on standardized uptake value (SUV) in 18F-FDG PET-scan: a systematic review and meta-analysis of 20,807 individual SUV measurements (2019) · cites this paper as [40]
Experimental — accuracy not yet measured
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
From RECIST to PERCIST: Evolving Considerations for PET Response Criteria in Solid Tumors
Wahl, R. L., Jacene, H., Kasamon, Y., & Lodge, M. A. (2009) · Journal of Nuclear Medicine · doi:10.2967/jnumed.108.057307 · Cited by 3,777 · cited 8×
“2-cm diameter (or 1-mL volume) spherical VOI [61] positioned such that the average value across all positions within the lesion is maximized.”
InfluentialUniversity of California, San Francisco
(1974) · Medical History · doi:10.1017/s0025727300019682 · Cited by 2,222
Young, H., Baum, R., Cremerius, U., Herholz, K., Hoekstra, O., Lammertsma, A. A., Pruim, J., & Price, P. (1999) · European Journal of Cancer · doi:10.1016/s0959-8049(99)00229-4 · Cited by 1,720
Self-citationBarrington, S. F., Mikhaeel, N. G., Kostakoglu, L., Meignan, M., Hutchings, M., Müeller, S. P., Schwartz, L. H., Zucca, E., Fisher, R. I., Trotman, J., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.53.5229 · Cited by 1,665 · cited 1×
“Further, a fivepoint scale has been proposed for assessment of lymphoma therapy response [80].”
Self-citationJuweid, M. E., Stroobants, S., Hoekstra, O. S., Mottaghy, F. M., Dietlein, M., Guermazi, A., Wiseman, G. A., Kostakoglu, L., Scheidhauer, K., Buck, A., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.08.2305 · Cited by 1,335 · cited 2×
“Some criteria have already been proposed [78, 79].”
Self-citationFDG PET and PET/CT: EANM procedure guidelines for tumour PET imaging: version 1.0
Boellaard, R., O’Doherty, M. J., Weber, W. A., Mottaghy, F. M., Lonsdale, M. N., Stroobants, S. G., Oyen, W. J. G., Kotzerke, J., Hoekstra, O. S., Pruim, J., et al. (2010) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-009-1297-4 · Cited by 1,326 · cited 6×
“• The effects of growth factors (G-CSF and GM-CSF) on FDG biodistribution (due to enhanced bone marrow uptake) generally last for more than 2 weeks after the final administration [20].”
InfluentialSelf-citationRecommendations on the Use of 18F-FDG PET in Oncology
Fletcher, J. W., Djulbegovic, B., Soares, H. P., Siegel, B. A., Lowe, V. J., Lyman, G. H., Coleman, R. E., Wahl, R., Paschold, J. C., Avril, N., et al. (2008) · Journal of Nuclear Medicine · doi:10.2967/jnumed.107.047787 · Cited by 1,101
Self-citationStandards for PET Image Acquisition and Quantitative Data Analysis
Boellaard, R. (2009) · Journal of Nuclear Medicine · doi:10.2967/jnumed.108.057182 · Cited by 902 · cited 4×
“This requires reconstruction settings to be chosen such as to achieve matching convergence and spatial resolution across various systems and sites, especially within a multicentre setting [48, 58, 59].”
InfluentialSelf-citationQuantification of Lean Bodyweight
Janmahasatian, S., Duffull, S. B., Ash, S., Ward, L. C., Byrne, N. M., & Green, B. (2005) · Clinical Pharmacokinetics · doi:10.2165/00003088-200544100-00004 · Cited by 900 · cited 1×
“[62]: LBM = 9,270 × weight/(6,680 + 216 × BMI) LBM = 9,270 × weight/(8,780 + 244 × BMI) where LBM and LBM are the LBM for males and females, and BMI is body mass index (weight/height), and weight and height are in kilograms and centimetres, respectively.”
Report on the First International Workshop on interim-PET scan in lymphoma
Meignan, M., Gallamini, A., Meignan, M., Gallamini, A., & Haioun, C. (2009) · Leukemia & Lymphoma · doi:10.1080/10428190903040048 · Cited by 754 · cited 2×
“Some criteria have already been proposed [78, 79].”
Procedure guideline for tumor imaging with 18F-FDG PET/CT 1.0.
Delbeke, D., Coleman, R. E., Guiberteau, M. J., Brown, M. L., Royal, H. D., Siegel, B. A., Townsend, D. W., Berland, L. L., Parker, J. A., Hubner, K., et al. (2006) · PubMed · Cited by 689
Self-citationShankar, L. K., Hoffman, J. M., Bacharach, S. L., Graham, M. M., Karp, J. S., Lammertsma, A. A., Larson, S. M., Mankoff, D. A., Siegel, B. A., den Abbeele, A. V., et al. (2006) · PubMed · Cited by 674
Self-citation(2004) · PubMed · Cited by 653
Self-citationProcedure guideline for tumor imaging with F-18 FDG PET/CT
Delbeke, D., Coleman, R. E., Guiberteau, M. J., Brown, M. L., Royal, H. D., Siegel, B. A., Townsend, D. W., Berland, L. L., Parker, J. A., Hübner, K. F., et al. (2006) · Cited by 620
Self-citationEANM/SNMMI Guideline for18F-FDG Use in Inflammation and Infection
Jamar, F., Buscombe, J., Chiti, A., Christian, P. E., Delbeke, D., Donohoe, K. J., Israel, O., Martin-Comin, J., & Signore, A. (2013) · Journal of Nuclear Medicine · doi:10.2967/jnumed.112.112524 · Cited by 577 · cited 2×
“[23] Jamar F, Buscombe J, Chiti A et al.”
Self-citation(1991) · Annals of the ICRP · doi:10.1016/0146-6453(91)90017-b · Cited by 565
Understanding the standardized uptake value, its methods, and implications for usage.
Thie, J. A. (2004) · PubMed · Cited by 546
EANM procedure guidelines for PET brain imaging using [18F]FDG, version 2
Varrone, A., Asenbaum, S., Vander Borght, T., Booij, J., Nobili, F., Någren, K., Darcourt, J., Kapucu, Ö. L., Tatsch, K., Bartenstein, P., et al. (2009) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-009-1264-0 · Cited by 544 · cited 4×
“& When dedicated brain imaging is indicated, additional preparation is necessary [39].”
InfluentialSelf-citationHuang, (. S.-C. (2000) · Nuclear Medicine and Biology · doi:10.1016/s0969-8051(00)00155-4 · Cited by 458 · cited 2×
“[31] Huang SC.”
A gradient-based method for segmenting FDG-PET images: methodology and validation
Geets, X., Lee, J. A., Bol, A., Lonneux, M., & Grégoire, V. (2007) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-006-0363-4 · Cited by 419 · cited 1×
“Other tumour segmentation methods have been described for MTVassessment and/or tumour delineation for radiotherapy planning in the literature, such as contrast-oriented methods [48, 83–85], gradient-based methods [86], iterative methods [87] and fuzzy clustering/segmentation methods [88].”
Boellaard, R., Oyen, W. J. G., Hoekstra, C. J., Hoekstra, O. S., Visser, E. P., Willemsen, A. T., Arends, B., Verzijlbergen, F. J., Zijlstra, J., Paans, A. M., et al. (2008) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-008-0874-2 · Cited by 396 · cited 3×
“0 mmol/L so that the SULs with (SULglu) and without (SUL) correction of glucose content are numerically practically identical (on average) [49].”
Self-citation(2008) · Annals of the ICRP · doi:10.1016/j.icrp.2008.08.003 · Cited by 390
Cook, G. J. R., Fogelman, I., & Maisey, M. N. (1996) · Seminars in Nuclear Medicine · doi:10.1016/s0001-2998(96)80006-7 · Cited by 381 · cited 1×
“Accumulation of FDG can normally be seen in the brain, heart, kidneys and urinary tract at 60 min after injection [66].”
Use of PET for monitoring cancer therapy and for predicting outcome.
Weber, W. (2005) · PubMed · Cited by 341
Self-citationWesterterp, M., Pruim, J., Oyen, W., Hoekstra, O., Paans, A., Visser, E., van Lanschot, J., Sloof, G., & Boellaard, R. (2007) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-006-0224-1 · Cited by 294 · cited 2×
“This requires reconstruction settings to be chosen such as to achieve matching convergence and spatial resolution across various systems and sites, especially within a multicentre setting [48, 58, 59].”
Self-citationBastiaannet, E., Groen, H., Jager, P. L., Cobben, D. C. P., van der Graaf, W. T. A., Vaalburg, W., & Hoekstra, H. J. (2004) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2003.07.004 · Cited by 294 · cited 1×
“FDG PET has been proven to be a sensitive imaging modality for detection, staging and restaging and therapy response assessment in oncology [1–13].”
Zhang, H., Wroblewski, K., Liao, S., Kampalath, R., Penney, B. C., Zhang, Y., & Pu, Y. (2013) · Academic Radiology · doi:10.1016/j.acra.2012.07.002 · Cited by 290 · cited 2×
“[71] Zhang H, Wroblewski K, Liao S et al.”
Krak, N. C., Boellaard, R., Hoekstra, O. S., Twisk, J. W. R., Hoekstra, C. J., & Lammertsma, A. A. (2005) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-004-1566-1 · Cited by 283 · cited 3×
“[81] Krak NC, Boellaard R, Hoekstra OS, Twisk JWR, Hoekstra CJ, Lammertsma AA.”
Self-citationThe royal college of radiologists
Steiner, R. E. (1980) · Clinical Radiology · doi:10.1016/s0009-9260(80)80176-0 · Cited by 278
Itti, E., Meignan, M., Berriolo-Riedinger, A., Biggi, A., Cashen, A. F., Véra, P., Tilly, H., Siegel, B. A., Gallamini, A., Casasnovas, R.-O., et al. (2013) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-013-2435-6 · Cited by 255
Hoekstra, C. J., Stroobants, S. G., Smit, E. F., Vansteenkiste, J., van Tinteren, H., Postmus, P. E., Golding, R. P., Biesma, B., Schramel, F. J. H. M., van Zandwijk, N., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.01.1189 · Cited by 247
Self-citationAcquisition protocol considerations for combined PET/CT imaging.
Beyer, T., Antoch, G., Müller, S. P., Egelhof, T., Freudenberg, L. S., Debatin, J. F., & Bockisch, A. (2004) · PubMed · Cited by 231
Self-citation(1969) · Radiology · doi:10.1148/23.1.186b · Cited by 220
Guidelines for 18F-FDG PET and PET-CT imaging in paediatric oncology
Stauss, J., Franzius, C., Pfluger, T., Juergens, K. U., Biassoni, L., Begent, J., Kluge, R., Amthauer, H., Voelker, T., Højgaard, L., et al. (2008) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-008-0826-x · Cited by 190
Self-citationAndrade, R. S., Heron, D. E., Degirmenci, B., Filho, P. A. A., Branstetter, B. F., Seethala, R. R., Ferris, R. L., & Avril, N. (2006) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2006.03.015 · Cited by 185 · cited 2×
“[73] Andrade RS, Heron DE, Degirmenci B et al.”
Standardised FDG uptake: A prognostic factor for inoperable non-small cell lung cancer
Borst, G. R., Belderbos, J. S. A., Boellaard, R., Comans, E. F. I., Jaeger, K. D., Lammertsma, A. A., & Lebesque, J. V. (2005) · European Journal of Cancer · doi:10.1016/j.ejca.2005.03.026 · Cited by 184 · cited 1×
“FDG PET has been proven to be a sensitive imaging modality for detection, staging and restaging and therapy response assessment in oncology [1–13].”
Self-citationBolton, R. C. D., Fernández, C., González-Maté, A., & Carreras, J. L. (2003) · PubMed · Cited by 183
Reduction of FDG uptake in brown adipose tissue in clinical patients by a single dose of propranolol
Söderlund, V., Larsson, S. A., & Jacobsson, H. (2007) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-006-0318-9 · Cited by 180 · cited 2×
“intravenous diazepam, administered 10 minutes prior to FDG [34], or 80 mg of propranolol given orally 2 hours before FDG administration [35]), but conflicting results have been reported [36].”
Monitoring response to treatment in patients utilizing PET
Avril, N. E., & Weber, W. A. (2005) · Radiologic Clinics of North America · doi:10.1016/j.rcl.2004.09.006 · Cited by 171 · cited 1×
“FDG PET has been proven to be a sensitive imaging modality for detection, staging and restaging and therapy response assessment in oncology [1–13].”
Self-citationChung, H. H., Kwon, H. W., Kang, K. W., Park, N.-H., Song, Y. S., Chung, J.-K., Kang, S., & Kim, J. (2011) · Annals of Surgical Oncology · doi:10.1245/s10434-011-2153-x · Cited by 160 · cited 2×
“• SUVs and related quantitative measures, such as metabolic tumour volume (MTV) and total lesion glycolysis (TLG), have gained increasing importance for therapy response monitoring [30, 61, 68] and for prognostic assessment [5, 69–71].”
For the EANM/SNMMI Paediatric Dosage Harmonization Working Group, Laßmann, M., & Treves, S. T. (2014) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-014-2731-9 · Cited by 158 · cited 2×
“Recommended administered activity at nominal weight (MBq) [51] See section VII 302 189 120 70”
Should clearance be normalised to body surface or to lean body mass?
Hallynck, T., Soep, H. H., Thomis, J. A., Boelaert, J. R., Daneels, R. F., & Dettli, L. (1981) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1981.tb01163.x · Cited by 155 · cited 2×
“[63] Hallynck TH, Soep HH, Thomis JA, Boelaert J, Daneels R, Dettli L.”
Schaefer, A., Kremp, S., Hellwig, D., Rübe, C., Kirsch, C., & Nestle, U. (2008) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-008-0875-1 · Cited by 154 · cited 1×
“Other tumour segmentation methods have been described for MTVassessment and/or tumour delineation for radiotherapy planning in the literature, such as contrast-oriented methods [48, 83–85], gradient-based methods [86], iterative methods [87] and fuzzy clustering/segmentation methods [88].”
Predictive and prognostic value of FDG‐PET in nonsmall‐cell lung cancer: A systematic review
de Geus‐Oei, L., van der Heijden, E. H. F. M., Corstens, F. H. M., & Oyen, W. J. G. (2007) · Cancer · doi:10.1002/cncr.22979 · Cited by 147 · cited 2×
“& SUVs and related quantitative measures, such as metabolic tumour volume (MTV) and total lesion glycolysis (TLG), have gained increasing importance for therapy response monitoring [30, 61, 68] and for prognostic assessment [5, 69–71].”
Self-citationAntoch, G., Kuehl, H., Kanja, J., Lauenstein, T. C., Schneemann, H., Hauth, E., Jentzen, W., Beyer, T., Goehde, S. C., & Debatin, J. F. (2004) · Radiology · doi:10.1148/radiol.2303021287 · Cited by 144 · cited 3×
“Nowadays, water or water-based contrast agents are often used as an intraluminal contrast medium that provides improved image quality with reduced artefact [44].”
InfluentialSelf-citationQuantifying the Effect of IV Contrast Media on Integrated PET/CT: Clinical Evaluation
Mawlawi, O. R., Erasmus, J. J., Munden, R. F., Pan, T., Knight, A. E., Macapinlac, H. A., Podoloff, D. A., & Chasen, M. H. (2006) · American Journal of Roentgenology · doi:10.2214/ajr.04.1740 · Cited by 143 · cited 2×
“[55] Mawlawi O, Erasmus JJ, Munden RF et al.”
Lasnon, C., Desmonts, C., Quak, E., Gervais, R., Dô, P., Dubos‐Arvis, C., & Aide, N. (2013) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-013-2391-1 · Cited by 132 · cited 2×
“Image quality and recovery coefficient harmonisation (IQRC) Although correct cross-calibration is guaranteed using the QC procedure described above, differences in SUV quantification may still occur between centres as a result of differences in the reconstruction and data analysis methodology [60, 100].”
James, W. P. T. (1977) · Nutrition Bulletin · doi:10.1111/j.1467-3010.1977.tb00966.x · Cited by 129
Procedure guideline for tumor imaging using fluorine-18-FDG. Society of Nuclear Medicine.
Schelbert, H. R., Hoh, C. K., Royal, H. D., Brown, M., Dahlbom, M. N., Dehdashti, F., & Wahl, R. L. (1998) · PubMed · Cited by 125
Laßmann, M., & Treves, S. T. (2014) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-014-2817-4 · Cited by 125 · cited 2×
“For children and adolescents, administered FDG activity should adhere to the EANM or SNMMI recommendations on paediatric radiopharmaceutical administration [51, 52] or national activity limits, if national limits are lower.”
Optimum Lean Body Formulation for Correction of Standardized Uptake Value in PET Imaging
Tahari, A. K., Chien, D. C., Azadi, J. R., & Wahl, R. L. (2014) · Journal of Nuclear Medicine · doi:10.2967/jnumed.113.136986 · Cited by 123 · cited 2×
“[65] Tahari AK, Chien D, Azadi JR, Wahl RL.”
Optimized dose regimen for whole-body FDG-PET imaging
de Groot, E. H., Post, N., Boellaard, R., Wagenaar, N., Willemsen, A. T. M., & van Dalen, J. A. (2013) · EJNMMI Research · doi:10.1186/2191-219x-3-63 · Cited by 120
Self-citationMeignan, M. A., Barrington, S. F., Itti, E., Gallamini, A., Haïoun, C., & Polliack, A. (2013) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2013.802784 · Cited by 115
Self-citationA novel iterative method for lesion delineation and volumetric quantification with FDG PET
van Dalen, J. A., Hoffmann, A. L., Dicken, V., Vogel, W. V., Wiering, B., Ruers, T. J. M., Karssemeijer, N., & Oyen, W. J. G. (2007) · Nuclear Medicine Communications · doi:10.1097/mnm.0b013e328155d154 · Cited by 114
Self-citationFrings, V., de Langen, A. J., Smit, E. F., van Velden, F. H. P., Hoekstra, O. S., van Tinteren, H., & Boellaard, R. (2010) · Journal of Nuclear Medicine · doi:10.2967/jnumed.110.077255 · Cited by 109 · cited 2×
“[82] Frings V, de Langen AJ, Smit EF et al.”
Self-citationESUR guidelines on contrast media
Thomsen, H. S., & Morcos, S. K. (2006) · Abdominal Imaging · doi:10.1007/s00261-005-0380-y · Cited by 108
Cheebsumon, P., Yaqub, M. M., van Velden, F. H. P., Hoekstra, O. S., Lammertsma, A. A., & Boellaard, R. (2011) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-011-1899-5 · Cited by 108 · cited 1×
“The authors realize the importance of using more accurate and improved delineation methods than those recommended above and, indeed, the use of more advanced methods is encouraged [89].”
Self-citationColeman, R. E., Delbeke, D., Guiberteau, M. J., Conti, P. S., Royal, H. D., Weinreb, J. C., Siegel, B. A., Federle, M. P., Townsend, D. W., & Berland, L. L. (2005) · PubMed · Cited by 108
Self-citationMasuda, Y., Kondo, C., Matsuo, Y., Uetani, M., & Kusakabe, K. (2009) · Journal of Nuclear Medicine · doi:10.2967/jnumed.108.060590 · Cited by 104 · cited 2×
“Literature suggests that FDG activities higher than 530 MBq for patients above 90 kg should not be applied for L(Y)SO systems [50].”
The role of positron emission tomography with 18 F-fluoro-2-deoxy-D-glucose in respiratory oncology
Vansteenkiste, J., & Stroobants, S. G. (2001) · European Respiratory Journal · doi:10.1183/09031936.01.17408020 · Cited by 103 · cited 1×
“FDG PET has been proven to be a sensitive imaging modality for detection, staging and restaging and therapy response assessment in oncology [1–13].”
Self-citationFrings, V., van Velden, F. H. P., Velasquez, L. M., Hayes, W., van de Ven, P. M., Hoekstra, O. S., & Boellaard, R. (2014) · Radiology · doi:10.1148/radiol.14132807 · Cited by 102 · cited 2×
“Other tumour segmentation methods have been described for MTVassessment and/or tumour delineation for radiotherapy planning in the literature, such as contrast-oriented methods [48, 83–85], gradient-based methods [86], iterative methods [87] and fuzzy clustering/segmentation methods [88].”
Self-citationMeta-analysis of the performance of 18F-FDG PET in cutaneous melanoma
Jiménez-Requena, F., Bolton, R. C. D., Fernández, C., Gambhir, S. S., Schwimmer, J., Pérez-Vázquez, J. M., & Carreras-Delgado, J. L. (2009) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-009-1224-8 · Cited by 93 · cited 1×
“FDG PET has been proven to be a sensitive imaging modality for detection, staging and restaging and therapy response assessment in oncology [1–13].”
Pattern of uptake and excretion of (18)F-FDG in the lactating breast.
Hicks, R. J., Binns, D. J., & Stabin, M. G. (2001) · PubMed · Cited by 93
Reference Range for Intrapatient Variability in Blood-Pool and Liver SUV for 18F-FDG PET
Boktor, R. R., Walker, G., Stacey, R., Gledhill, S., & Pitman, A. G. (2013) · Journal of Nuclear Medicine · doi:10.2967/jnumed.112.108530 · Cited by 90 · cited 2×
“[95] Boktor RR, Walker G, Stacey R, Gledhill S, Pitman AG.”
Larson, S. M., & Schwartz, L. H. (2006) · PubMed · Cited by 87
Coleman, R. E., Delbeke, D., Guiberteau, M. J., Conti, P. S., Royal, H. D., Weinreb, J. C., Siegel, B. A., Federle, M. P., Townsend, D. W., & Berland, L. L. (2005) · Journal of the American College of Radiology · doi:10.1016/j.jacr.2005.03.014 · Cited by 85 · cited 1×
“An overview of other and previously published guidelines [10, 21, 61, 68, 78, 99–106] or recommendations can be found in the supplement issue of the Journal of Nuclear Medicine 2009 [58].”
Self-citationFuzzy hidden Markov chains segmentation for volume determination and quantitation in PET
Hatt, M., Lamare, F., Boussion, N., Turzo, A., Collet, C., Salzenstein, F., Roux, C., Jarritt, P. H., Carson, K. J., Rest, C. C. L., et al. (2007) · Physics in Medicine and Biology · doi:10.1088/0031-9155/52/12/010 · Cited by 79 · cited 1×
“Other tumour segmentation methods have been described for MTVassessment and/or tumour delineation for radiotherapy planning in the literature, such as contrast-oriented methods [48, 83–85], gradient-based methods [86], iterative methods [87] and fuzzy clustering/segmentation methods [88].”
How should we analyse FDG PET studies for monitoring tumour response?
Lammertsma, A. A., Hoekstra, C. J., Giaccone, G., & Hoekstra, O. S. (2006) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-006-0131-5 · Cited by 79 · cited 1×
“An overview of other and previously published guidelines [10, 21, 61, 68, 78, 99–106] or recommendations can be found in the supplement issue of the Journal of Nuclear Medicine 2009 [58].”
Self-citationLockhart, C. M., MacDonald, L. R., Alessio, A. M., McDougald, W., Doot, R. K., & Kinahan, P. E. (2011) · Journal of Nuclear Medicine · doi:10.2967/jnumed.110.083865 · Cited by 79 · cited 2×
“[97] Lockhart CM, MacDonald LR, Alessio AM, McDougald WA, Doot RK, Kinahan PE.”
FDG-PET/CT in oncology*: German Guideline
Krause, B. J., Beyer, T., Bockisch, A., Delbeke, D., Kotzerke, J., Minkov, V., Reiser, M. F., & Willich, N. (2007) · Nuklearmedizin - NuclearMedicine · doi:10.3413/nukmed-282 · Cited by 72 · cited 3×
“FDG PET/CT in Oncology Page 46 of 46 [101] Krause BJ, Beyer T, Bockisch A et al.”
Self-citationAcceptance testing for nuclear medicine instrumentation
Sokole, E. B., Płachcińska, A., & Britten, A. J. (2010) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-009-1348-x · Cited by 67 · cited 2×
“[18] Busemann SE, Plachcinska A, Britten A.”
Lasnon, C., Hicks, R. J., Beauregard, J., Milner, A. D., Paciencia, M., Guizard, A., Bardet, S., Gervais, R., Lemoel, G., Zalcman, G., et al. (2012) · Clinical Nuclear Medicine · doi:10.1097/rlu.0b013e318251e3d1 · Cited by 65 · cited 2×
“Image quality and recovery coefficient harmonisation (IQRC) Although correct cross-calibration is guaranteed using the QC procedure described above, differences in SUV quantification may still occur between centres as a result of differences in the reconstruction and data analysis methodology [60, 100].”
Fencl, P., Bělohlávek, O., Skopalová, M., Jarůšková, M., Kantorová, I., & Šimonová, K. (2007) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-007-0456-8 · Cited by 61
Integration of FDG- PET/CT into external beam radiation therapy planning
Beyer, T., Boellaard, R., Ruysscher, D. D., Grgic, A., Lee, J. A., Pietrzyk, U., Sattler, B., Schaefer, A., van Elmpt, W., Vogel, W. V., et al. (2012) · Nuklearmedizin - NuclearMedicine · doi:10.3413/nukmed-0455-11-12 · Cited by 59
Self-citationFDG-PET of patients with suspected renal failure: standardized uptake values in normal tissues
Minamimoto, R., Takahashi, N., & Inoue, T. (2007) · Annals of Nuclear Medicine · doi:10.1007/s12149-007-0012-4 · Cited by 58 · cited 2×
“FDG imaging can be performed in patients with kidney failure, although the image quality may be suboptimal and prone to interpretation pitfalls [33].”
Absorbed 18F-FDG Dose to the Fetus During Early Pregnancy: FIGURE 1.
Zanotti‐Fregonara, P., Jan, S., Taïeb, D., Cammilleri, S., Trébossen, R., Hindié, E., & MUNDLER, O. (2010) · Journal of Nuclear Medicine · doi:10.2967/jnumed.109.071878 · Cited by 57 · cited 2×
“[26] Zanotti-Fregonara P, Jan S, Taieb D et al.”
Lum, D. (2002) · Molecular Imaging and Biology · doi:10.1016/s1095-0397(01)00062-0 · Cited by 51 · cited 2×
“[38] Lum DP, Wandell S, Ko J, Coel MN.”
Suppression of myocardial 18F-FDG uptake with a preparatory “Atkins-style” low-carbohydrate diet
Coulden, R. A., Chung, P., Sonnex, E., Ibrahim, Q. I., Maguire, C., & Abele, J. (2012) · European Radiology · doi:10.1007/s00330-012-2478-2 · Cited by 50 · cited 1×
“instructions for the patient to follow a low carbohydrate diet for 24 h prior to the PET/CT study, or at least a low carbohydrate meal before starting the 6-h period of fasting before the study [37, 38].”
Clinical use of PET-CT data for radiotherapy planning: What are we looking for?
Chiti, A., Kirienko, M., & Grégoire, V. (2010) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2010.07.021 · Cited by 48
Self-citationReporting Guidance for Oncologic 18F-FDG PET/CT Imaging
Niederkohr, R. D., Greenspan, B. S., Prior, J. O., Schöder, H. M., Seltzer, M., Zukotynski, K., & ROHREN, E. M. (2013) · Journal of Nuclear Medicine · doi:10.2967/jnumed.112.112177 · Cited by 48 · cited 5×
“For further reading also see the Society of Nuclear Medicine and Molecular Imaging’s reporting guidance for oncological FDG PET/CT imaging [76], the Royal College of Radiologists’ recommendations on reporting [77] and the Society of Nuclear Medicine and Molecular Imaging’s Procedure Standard for General Imaging.”
InfluentialPET/CT (and CT) instrumentation, image reconstruction and data transfer for radiotherapy planning
Sattler, B., Lee, J. A., Lonsdale, M. N., & Coche, E. (2010) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2010.07.009 · Cited by 45 · cited 2×
“[94] Sattler B, Lee JA, Lonsdale M, Coche E.”
FDG PET in lymphoma: The need for standardization of interpretation. An observer variation study
Zijlstra, J., Comans, E., van Lingen, A., Hoekstra, O., Gundy, C., Coebergh, J. W., & Bongers, V. (2007) · Nuclear medicine communications · doi:10.1097/mnm.0b013e3282eff2d5 · Cited by 44 · cited 1×
“An overview of other and previously published guidelines [10, 21, 61, 68, 78, 99–106] or recommendations can be found in the supplement issue of the Journal of Nuclear Medicine 2009 [58].”
Self-citationAccuracy of the EasyTouch blood glucose self-monitoring system: a study of 516 cases
Dai, K.-S., Tai, D.-Y., Ho, P., Chen, C.-C., Peng, W.-C., Chen, S.-T., Hsu, C.-C., Liu, Y.-P., Hsieh, H.-C., Yang, C.-C., et al. (2004) · Clinica Chimica Acta · doi:10.1016/j.cccn.2004.06.010 · Cited by 41 · cited 2×
“Note that many bedside methods do not have sufficient precision to be used for SUV glucose correction [29].”
Bailey, D. L., Barthel, H., Beyer, T., Boellaard, R., Gückel, B., Hellwig, D., Herzog, H. R., Pichler, B. J., Quick, H. H., Sabri, O., et al. (2013) · Molecular Imaging and Biology · doi:10.1007/s11307-013-0623-1 · Cited by 40
Self-citationBailey, D. L., Barthel, H., Beuthien‐Baumann, B., Beyer, T., Bisdas, S., Boellaard, R., Czernin, J. G., Drzezga, A. E., Ernemann, U., Franzius, C., et al. (2014) · Molecular Imaging and Biology · doi:10.1007/s11307-014-0725-4 · Cited by 39
Self-citation(2008) · Annals of the ICRP · doi:10.1016/j.icrp.2008.08.002 · Cited by 39
18F-FDG PET/CT of Patients With Cancer: Comparison of Whole-Body and Limited Whole-Body Technique
Osman, M., Chaar, B. T., Muzaffar, R., Oliver, D. A., Reimers, H. J., Walz, B. J., & Nguyen, N. C. (2010) · American Journal of Roentgenology · doi:10.2214/ajr.09.3731 · Cited by 38 · cited 2×
“[53] Osman MM, Chaar BT, Muzaffar R et al.”
Bourguet, P., Blanc-Vincent, M. P., Boneu, A., Bosquet, L., Chauffert, B., Corone, C., Courbon, F., Devillers, A., Foehrenbach, H., Lumbroso, J., et al. (2003) · British Journal of Cancer · doi:10.1038/sj.bjc.6601088 · Cited by 38
PET in radiotherapy planning: Particularly exquisite test or pending and experimental tool?
Grégoire, V., & Chiti, A. (2010) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2010.07.015 · Cited by 37
Self-citationPET and PET/CT Reports: Observations from the National Oncologic PET Registry
Coleman, R. E., Hillner, B. E., Shields, A. F., Duan, F., Merlino, D. A., Hanna, L., Stine, S. H., & Siegel, B. A. (2009) · Journal of Nuclear Medicine · doi:10.2967/jnumed.109.066399 · Cited by 37
Thorwarth, D., Beyer, T., Boellaard, R., Ruysscher, D. D., Grgic, A., Lee, J. A., Pietrzyk, U., Sattler, B., Schaefer, A., van Elmpt, W., et al. (2012) · Nuklearmedizin - NuclearMedicine · Cited by 34
Self-citationInternational Guidelines for Pediatric Radiopharmaceutical Administered Activities
Treves, S. T., Laßmann, M., & for the EANM/SNMMI Pediatric Dosage Harmonization Working Group (2014) · Journal of Nuclear Medicine · doi:10.2967/jnumed.114.139980 · Cited by 32 · cited 2×
“[52] Treves ST, Lassmann M.”
Gadd, R., Baker, M., Nijran, K. S., Owens, S. R., Thomas, W., Woods, M. J., & Zananiri, F. V. (2006) · Cited by 32
Nestle, U., Kremp, S., Hellwig, D., Grgic, A., Buchholz, H. G., Mischke, W., Gromoll, C., Dennert, P., Plotkin, M., Senftleben, S., et al. (2012) · Nuklearmedizin - NuclearMedicine · doi:10.3413/nukmed-0452-11-12 · Cited by 31 · cited 1×
“Other tumour segmentation methods have been described for MTVassessment and/or tumour delineation for radiotherapy planning in the literature, such as contrast-oriented methods [48, 83–85], gradient-based methods [86], iterative methods [87] and fuzzy clustering/segmentation methods [88].”
The effect of oral contrast on large bowel activity in FDG-PET/CT
Otsuka, H., Graham, M. M., Kubo, A., & Nishitani, H. (2005) · Annals of Nuclear Medicine · doi:10.1007/bf03027388 · Cited by 31 · cited 1×
“However, administration of water only as a negative intraluminal contrast agent itself is associated with fast reabsorption and can cause increased nonspecific FDG accumulation in the bowel [57].”
Self-citationMolecular Imaging in Radiotherapy Planning for Head and Neck Tumors: FIGURE 1.
Grégoire, V., & Chiti, A. (2011) · Journal of Nuclear Medicine · doi:10.2967/jnumed.110.075689 · Cited by 27 · cited 2×
“[93] Gregoire V, Chiti A.”
Self-citationSturkenboom, M. G. G., Hoekstra, O. S., Postema, E. J., Zijlstra, J. M., Berkhof, J. H., & Franssen, E. J. F. (2009) · Molecular Imaging and Biology · doi:10.1007/s11307-009-0207-2 · Cited by 25 · cited 2×
“[36] Sturkenboom MG, Hoekstra OS, Postema EJ, Zijlstra JM, Berkhof J, Franssen EJ.”
Self-citationGreuter, H. N. J. M., Boellaard, R., van Lingen, A., Franssen, E. J. F., & Lammertsma, A. A. (2003) · PubMed · Cited by 25
Self-citationCaobelli, F., Pizzocaro, C., Paghera, B., & Guerra, U. P. (2012) · Nuclear Medicine Communications · doi:10.1097/mnm.0b013e32835d1034 · Cited by 21 · cited 2×
“[32] Caobelli F, Pizzocaro C, Paghera B, Guerra UP.”
Intravenous iodinated contrast agents: risks and problematic situations.
Bui, K. L., Horner, J. D., Herts, B. R., & Einstein, D. M. (2007) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.74.5.361 · Cited by 21 · cited 4×
“Discontinuing diuretics, non-steroidal anti-inflammatory agents and aminoglycosides may also decrease contrast-induced renal failure [40, 41].”
InfluentialIntravenous administration of diazepam significantly reduces brown fat activity on 18F-FDG PET/CT.
Rakheja, R., Ciarallo, A., Alabed, Y. Z., & Hickeson, M. P. (2011) · Europe PMC (PubMed Central) · Cited by 19
The Use of PET for Radiotherapy
Erdi, Y. E. (2007) · Current Medical Imaging Formerly Current Medical Imaging Reviews · doi:10.2174/1573405610703010003 · Cited by 17 · cited 1×
“FDG PET has been proven to be a sensitive imaging modality for detection, staging and restaging and therapy response assessment in oncology [1–13].”
The role of FDG PET-CT in the therapeutic evaluation for HNSCC patients
Kawabe, J., Higashiyama, S., Yoshida, A., Kotani, K., & Shiomi, S. (2012) · Japanese Journal of Radiology · doi:10.1007/s11604-012-0076-5 · Cited by 13 · cited 2×
“[74] Kawabe J, Higashiyama S, Yoshida A, Kotani K, Shiomi S.”
Miller, J. C., Fischman, A. J., Aquino, S. L., Blake, M. A., Thrall, J. H., & Lee, S. I. (2007) · Journal of the American College of Radiology · doi:10.1016/j.jacr.2006.10.011 · Cited by 12 · cited 1×
“An overview of other and previously published guidelines [10, 21, 61, 68, 78, 99–106] or recommendations can be found in the supplement issue of the Journal of Nuclear Medicine 2009 [58].”
Cumulative index to the annual catalogues of Her Majesty's Stationery Office publications, 1922-1972
Blackmore, R. M., & Ollé, J. G. (1976) · UT Back-in-Print Service eBooks · Cited by 9
[18F]FDG-PET scan in patients with fasting hyperglycemia.
Bělohlávek, O., & Jarůšková, M. (2016) · PubMed · Cited by 9
A Systematic Review of the Efficacy of 18F-FDG PET in Unknown Primary Tumors
Bolton, R. C. D., Carreras, J., & Pérez-Castejón, M. J. (2006) · Current Medical Imaging Formerly Current Medical Imaging Reviews · doi:10.2174/157340506776930601 · Cited by 6
Research works printed but not linked: 1
- Padhani AR. Imaging in the evaluation of cancer. In: Nicholson T, editor. Recommendations for cross-sectional imaging in cancer management. 2nd ed. London: The Royal College of Radiologists; 2014.
Cited by
Zwanenburg, A., Vallières, M., Abdalah, M. A., Aerts, H. J. W. L., Andrearczyk, V., Apte, A., Ashrafinia, S., Bakas, S., Beukinga, R. J., Boellaard, R., et al. (2020) · Radiology · doi:10.1148/radiol.2020191145 · Cited by 4,177
Self-citationApplications and limitations of radiomics
Yip, S. S. F., & Aerts, H. J. W. L. (2016) · Physics in Medicine and Biology · doi:10.1088/0031-9155/61/13/r150 · Cited by 1,210
Imaging biomarker roadmap for cancer studies
O'Connor, J. P. B., Aboagye, E. O., Adams, J. E., Aerts, H. J. W. L., Barrington, S. F., Beer, A. J., Boellaard, R., Bohndiek, S. E., Brady, M., Brown, G., et al. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.162 · Cited by 1,091
“ADC, the family of K and related perfusion biomarkers derived from either CT or MRI and (18)F-fluorothymidine PET) continue to be measured and analysed in disparate ways by different laboratories using a wide range of software systems, despite attempts to standardise and harmonise these methods (2, 3, 11-14).”
Self-citationLactate: the ugly duckling of energy metabolism
Rabinowitz, J. D., & Enerbäck, S. (2020) · Nature Metabolism · doi:10.1038/s42255-020-0243-4 · Cited by 1,049
Guidelines for the Diagnosis and Treatment of Hepatocellular Carcinoma (2019 Edition)
Zhou, J., Sun, H., Wang, Z., Cong, W., Wang, J., Zeng, M., Zhou, W., Bie, P., Liu, L., Wen, T., et al. (2020) · Liver Cancer · doi:10.1159/000509424 · Cited by 800
Metadata
- Authors
- Boellaard, R., Delgado-Bolton, R., Oyen, W. J. G., Giammarile, F., Tatsch, K., Eschner, W., Verzijlbergen, F. J., Barrington, S. F., Pike, L. C., Weber, W. A., Stroobants, S., Delbeke, D., Donohoe, K. J., Holbrook, S., Graham, M. M., Testanera, G., Hoekstra, O. S., Zijlstra, J., Visser, E., Hoekstra, C. J., Pruim, J., Willemsen, A., Arends, B., Kotzerke, J., Bockisch, A., Beyer, T., Chiti, A., & Krause, B. J.
- Affiliations
- Amsterdam UMC Location Vrije Universiteit Amsterdam (NL)
- Radboud University Medical Center (NL)
- Hospices Civils de Lyon (FR)
- Städtisches Klinikum Karlsruhe (DE)
- University of Cologne (DE)
- Erasmus MC (NL)
- St Thomas' Hospital (GB)
- Memorial Sloan Kettering Cancer Center (US)
- Antwerp University Hospital (BE)
- Vanderbilt University Medical Center (US)
- Beth Israel Deaconess Medical Center (US)
- Insilico Medicine (United States) (US)
- University of Iowa (US)
- Humanitas University (IT)
- Jeroen Bosch Ziekenhuis (NL)
- University Medical Center Groningen (NL)
- Catharina Ziekenhuis (NL)
- University Hospital Carl Gustav Carus (DE)
- Essen University Hospital (DE)
- Medical University of Vienna (AT)
- Universitätsmedizin Rostock (DE)
- Corresponding author
- Boellaard, Ronald
- ORCID
- Venue
- European Journal of Nuclear Medicine and Molecular Imaging
- Published
- 2014-12-02
- Volume
- 42
- Issue
- 2
- Pages
- 328-354
- ISSN
- 1619-7070 (ISSN-L)
- 1619-7089
- PMC
- PMC4315529
- OpenAlex
- W2088783247
- Cited by
- 3,303
- References
- 109
- Citations by year
- 2026: 306 · 2025: 341 · 2024: 388 · 2023: 333 · 2022: 405 · 2021: 408 · 2020: 296 · 2019: 258 · 2018: 230 · 2017: 159 · 2016: 115 · 2015: 54
- FWCI
- 85.55
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- European Journal of Nuclear Medicine and Molecular Imaging (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Kölner Universitäts PublikationsServer (Universität zu Köln) (publishedVersion)
- Amsterdam UMC (VU Amsterdam) - Institutional Repository (publishedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (publishedVersion)
- Pure Amsterdam UMC (acceptedVersion, other-oa)
- EUR Research Repository (Erasmus University Rotterdam) (submittedVersion)
- Universitätsbibliographie, Universität Duisburg-Essen (submittedVersion)
- Research Portal (King's College London) (submittedVersion, other-oa)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion, cc-by)
- Radboud Repository (Radboud University) (submittedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Topics
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Medical Imaging Techniques and Applications
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Radiomics and Machine Learning in Medical Imaging
- Keywords
- FDG PET/CT, tumor imaging, standardized uptake value, quantitative imaging, quality control, quality assurance, repeatability, reproducibility, imaging biomarkers, tumor response assessment, tumor staging, cancer diagnosis, cancer prognosis, EANM guidelines
- MeSH terms
- Humans, Neoplasms, Tomography, X-Ray Computed, Radiopharmaceuticals, Fluorodeoxyglucose F18, Positron-Emission Tomography, Multimodal Imaging
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.